Selectivity in human breast cancer and human bone marrow using trimetrexate in combination with 5-fluorouracil

Anticancer Research

Volumn 19, Issue 5 B, 1999, Pages 3837-3840

  Bowen, Donnell ^a   Johnson, Donna H ^a   Southerland, William M ^a   Hughes, Doris E ^a   Hawkins Jr , Morris ^a  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

5 Fluorouracil; Bone marrow; Breast cancer; Trimetrexate

Indexed keywords

FLUOROURACIL; TRIMETREXATE;

ARTICLE; BONE MARROW; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CELL GROWTH; CELL STRAIN MCF 7; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0032779135     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Kamen BA, Eibl B, Cashmore A and Bertino J: Uptake and efficacy of trimetrexate, a non-classical antifolate in methotrexate-resistant leukemia cells in vitro. Biochem. Pharmacol 33: 1697-1699, 1984.
2. Fry DW and Besserer JA: Characterization of trimetrexate transport in human lymhoblastoid cells and development of impaired influx as a mechanism of resistance to lipophilic antifolates. Cancer Res 48: 6986-6991, 1988.
3. Jackson RC, Fry DW, Boritzki TJ, Besserer JA, Leopold WR, Sloan BJ and Elslager EF: Biochemical pharmacology of the lipophilic antifolate, trimetrexate. Adv Enzyme Regul 22: 187-206, 1984
4. Bertino JR, Sawicki WL, Moroson BA, Cashmore AR and Elslager EF: 2,4-diamino-5-methyl-[(3,4,5-trimethoxyanilino)methyl]-quinazoline (TMQ), a potent non-classical folate antagonist inhibitor. I. Effect on dihydrofolate reductase and growth of rodent tumors in vitro and in vivo. Biochem Pharmacol 28: 1983-1987, 1979.
5. Mini E, Moroson A, Franco CT and Bertino JR: Cytotoxic effects of folate antagonists against methotrexate-resistant human leukemic lymphoblast CCRF-CEM cell lines. Cancer Res 45: 325-330, 1985.
6. Bertino JR: Biomodulatioin of 5-fluorouracil with antifolates. Semin Oncol 24(5 Suppl. 18): S18-52-S18-56, 1997.
7. Blanke CD, Kasimis B, Schein P, Capizzi R and Kurman M: Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer. J Clin Oncol 15: 915-920, 1997.
8. Warren E, George S, You J and Kazanjian P: advances in the treatment and prophylaxis of Pneumocystis carinii pneumonia. Pharmacotherapy 17: 900-916, 1997.
9. Sobrero A, Romanni A, Russello O, Nicolin A, Rosso R and Bertino JR: Sequence-dependent enhancement of HCT-8 cell kill by trimetrexate and fluoropyrimidines: Implications for the mechanism of this reaction. Eur J Cancer Clin Oncol 25: 977-982, 1989.
10. Elliott WL, Howard CT, Dykes DJ and Leopold WR: Sequence and schedule-dependent synergy of trimetrexate in combination with 5-fluorouracil in vitro and in mice. Cancer Res 49: 5586-5590, 1989
11. Lin JT and Bertino JR: Update on trimetrexate, a folate antagonist with antineoplastic and antiprotozoal properties. Cancer Investigation 9: 159-172, 1991.
12. Spencer HT, Sleep SE, Rehg JE, Blakely RL and Sorrentino BP: A gene transfer strategy for making bone marrow cells resistant to trimetrexate. Blood 87: 2579-2587, 1996.
13. Bowen D, Johnson DH, Southerland WM, Hughes DE and Hawkins M: 5-Fluorouracil simultaneously maintains methotrexate antineoplastic activity in human breast cancer and protects against methotrexate cytotoxicity in human bone marrow. Anticancer Res 19(2): 985-988, 1999.
14. White RM: 5-Fluorouracil modulates the toxicity of high dose methotrexate. J Clin Pharmacol 35: 1156-1165, 1995
15. Allegra CJ, Drake JC, Jolivet J and Chabner BA: Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolate polyglutamates. Proc Natl Acad Sci U.S.A. 82: 4881-4885, 1985.
16. Chu E, Drake JC, Boarman D, Baram J and Allegra CJ: Mechanism of thymidylate synthase inhibition by methotrexate in human neoplastic cell lines and normal human myeloid progenitor cells. J Biol Chem 265: 8470-8478, 1990.
17. Matthews RG and Baugh CM: Interactions of pig liver methylenetetrahydrofolate reductase with methyenetetrahydropteroylpolyglutamate substrates and with dihydropteroylpolyglutamate inhibitors. Biochemistry 19: 2040-2045, 1980.